Navigation Links
Access Pharmaceuticals Presents New Data at International Symposium Showing Company's Angiolix(R) Monoclonal Antibody has Potential to Treat Cancer by Attacking Cancer Stem Cells
Date:6/26/2008

bination with conventional chemotherapy regimes, as well as compare its efficacy with other anti-angiogenesis drugs, such as Avastin.

The Company is actively seeking potential partners for the further clinical development of Angiolix, a drug which holds great promise as an anti-vascular cancer therapy.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; Prodrax(R), a non-toxic prodrug which is activated in the hypoxic zones of solid tumors to kill cancer cells; Alchemix, a chemotherapeutic agent that combines multiple modes of action to overcome drug resistance. For additional information on Access Pharmaceuticals, please visit our website at http://www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our ability to close the financing transaction, early results from our clinical trial, Access' plans to continue and initiate clinical trials, the value of its products in the market, its ability to achieve clinical and commercial success and its ability to successfully develop marketed products. These statements are subject t
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application
2. A Perfect Storm Threatens Patient Access to Specialty Medical Care
3. AMT Makes Important Advance in the Development of its Gene Therapy for Hemophilia B -Company Accesses Technology to Prevent Immune Response
4. Access Licenses ProLindac(TM) to Jiangsu Aosaikang Pharmaceutical Co., LTD., a Leading Oncology Pharmaceutical Company for Manufacturing, Development and Commercialization in the Greater China Region
5. HistoRx Announces Expanded Access of AQUA(R) Technology to 900+ Researchers at Dana-Farber/Harvard Cancer Center
6. AMT Accesses Technology for Treatment of Duchenne Muscular Dystrophy
7. Access Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
8. SurgiQuest Announces First Single Port Procedure for Ovary Removal Using AirSeal(TM) Access System
9. Scientists call for more access to biotech crop data
10. Perceptive Informatics Improves Clinical Site Monitoring Access and Flexibility With Portable USB Drive Capability
11. Canadian Centre for DNA Barcoding to Participate in Microchip Biotechnologies Early Access Program for Microchip-Based DNA Sample Preparation and Cycle Sequencing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... (PRWEB) January 14, 2014 Histogen, Inc., ... products of cells grown under simulated embryonic conditions, today ... agreement with Suneva Medical, Inc. for physician-dispensed aesthetic products ... , This agreement is an amendment to the ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging ... to serve the wound care market. , Free report ... was restructured with a seasoned management team and Board, ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management software, today ... In this role, Michelle will work with current and potential ... development of iLab products. Her main goal will be to ... scientific community by offering the most advanced, user-friendly, and high-impact ...
(Date:1/14/2014)... Global Record Systems, LLC, (GRS), a ... for patients, physicians, the biopharmaceutical industry, regulators, payers, ... signing of a three-year Research Collaboration Agreement (RCA) ... This initiative is designed to generate disruptive ...
Breaking Biology Technology:Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... (Nasdaq and SWX: BMRN) announced today the appointment,of ... Former Vice President of,Research and Development for Raven ... patents and the recipient of a,collection of prestigious ... Awards from Intellectual Property Owners, Inc., "We ...
... Therapeutics Inc., an,early stage biotechnology company developing therapies ... Drug application (IND),to the U.S. Food and Drug ... the first-in-man clinical trials for its lead compound,VEL-0230., ... has dual-acting properties, in,that it both stimulates bone ...
... N.J., Jan. 28 Ferring Pharmaceuticals Inc.,has announced ... will serve as the title sponsor of the ... GeezerJock of the Year,Award., "This is such ... for,senior athletes," said Alex Drigan, Product Manager, EUFLEXXA(TM). ...
Cached Biology Technology:BioMarin Appoints Dr. Gordon Vehar, Vice President of Research 2BioMarin Appoints Dr. Gordon Vehar, Vice President of Research 3Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA 2Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award 2Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award 3Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award 4
(Date:4/23/2014)... School of Public Health-Bloomington has bolstered the link between ... strong association between heme iron, found only in meat, ... found that heme iron consumption increased the risk for ... was found between nonheme iron, which is in plant ... The study was published online ahead of print in ...
(Date:4/23/2014)... in their mid-thirties and forties, face a devastating ... two decades. "Mutant" protein clusters, long blamed for ... the primary focus of therapies in development by ... Prof. Gerardo Lederkremer and Dr. Julia Leitman of ... Immunology, in collaboration with Prof. Ulrich Hartl of ...
(Date:4/23/2014)... Scarborough research shows that male black widow spiders prefer ... rare example of mate preference by male spiders. ... MacLeod and Maydianne Andrade, a professor in UTSC,s Department ... and the wild that males overwhelmingly chose to mate ... widows can tell whether a potential mate is well-fed ...
Breaking Biology News(10 mins):Study: Iron consumption can increase risk for heart disease 2On the defensive 2On the defensive 3Picky male black widow spiders prefer well-fed virgins 2
... found a new way that DNA can carry out its ... mold used to cast a metal tool can also serve ... distinct functional roles. Professor Manolis Kellis and postdoctoral research ... the journal Genes & Development that in certain DNA sequences, ...
... E-Ticketing Solution from BIO-key and Advanced Public Safety ... Officer Risk, Reduces Cost and Increases ... Fla., Jan. 10 /PRNewswire-FirstCall/,-- BIO-key International, Inc. (OTC ... and wireless public safety solutions,and Advanced Public Safety ...
... Cold Spring Harbor, NY Cold Spring Harbor Laboratorys ... Joans Legacy: The Joan Scarangello Foundation to Conquer Lung ... cancer research involving a new class of genetic mutations ... lung cancer, the leading cause of cancer deaths in ...
Cached Biology News:MIT reports new twist in microRNA biology 2Missouri Police Department Introduces Electronic Traffic Citations 2Missouri Police Department Introduces Electronic Traffic Citations 3Missouri Police Department Introduces Electronic Traffic Citations 4Cold Spring Harbor Laboratory's lung cancer research program awarded $100,000 grant 2
Features , Designed to assist users in applying domed caps to tube strips and plates , Minimises the pressure required to seal the caps effectively , Enables multiple tubes to be sealed simultaneousl...
Request Info...
Sterile, individually wrapped, 4mm Cuvettes...
versican (H-56)...
Biology Products: